Clearside Biomedi (CLSD)

$1.56 0.11 (7.59%)

16:00 EDT CLSD Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap 49.84M

PE Ratio -0.61

EPS -2.54

Volume (Avg. Vol.) 62,200

Day's Range 1.48 - 1.56

52-Week Range 0.60 - 4.13

Dividend & Yield N/A (N/A)

CLSD Stock Predictions, Articles, and Clearside Biomedi News

From InvestorPlace
From the Web

5 ‘Strong Buy’ Biotechs That Can Double in 2018

By Harriet Lefton, Writer, TipRanks Mar 14, 2018

Here are five 'Strong Buy' biotech stocks with potential upside of over 100%. These five innovative stocks are worth tracking over the coming months according to the Street.

Clearside Biomedical presents at the Retina Society 2020 and publication of XIPERE data (NASDAQ:CLSD)

From Seeking Alpha Sep 23, 2020

Clearside Biomedical (CLSD) announced several clinical data presentations were given at the virtual 53rd Annual Scientific Meeting of The Retina Society.

Mid-stage study underway on eye drug administered with Clearside microinjector (NASDAQ:CLSD)

From Seeking Alpha Sep 11, 2020

Clearside Biomedical (NASDAQ:CLSD) announces that licensee Aura Biosciences has dosed the first patient in its Phase 2 trial evaluating the safety and efficacy of suprachoroidal administration of light-activated AU-011 as a potential first-line treatment of patients with primary choroidal melanoma (type of eye cancer).Aura is using Clearside’s SCS Microinjector to deliver AU-011 into the suprachoroidal space.Aura also announced that AU-011 passed the Safety Review for the first dose escalation cohort which demonstrated favorable safety data with no safety findings and no adverse events noted.“With this trial initiation, we are on track to have three product candidates delivered via our SCS Microinjector in four clinical trials this year,” said Thomas Ciulla, Chief Medical Officer and Chief Development Officer of ClearsideCLSD is +3.6% in premarket

Dosing is underway for Clearside/Aura Biosciences's AU-011 in mid-stage study for eye cancer (NASDAQ:CLSD)

From Seeking Alpha Sep 11, 2020

Clearside Biomedical (NASDAQ:CLSD) has announced that its licensing partner, Aura Biosciences, has dosed the first patient in its Phase 2 trial evaluating the safety and efficacy of suprachoroidal administration of AU-011 as a potential first-line treatment for patients with primary choroidal melanoma (eye cancer).Aura is using Clearside’s SCS Microinjector to deliver AU-011 into the suprachoroidal space.Aura also announced that AU-011 passed the Safety Review for the first dose escalation cohort which demonstrated favorable safety data with no safety findings and no adverse events noted.“With this trial initiation, we are on track to have three product candidates delivered via our SCS Microinjector in four clinical trials this year,” said Thomas Ciulla, Chief Medical Officer and Chief Development Officer of ClearsideCLSD is +3.6% in premarket

Clearside Biomedical’s licensing partner doses first patient in its Phase 2 therapy trial, shares rallies 13% (NASDAQ:CLSD)

From Seeking Alpha Sep 9, 2020

Clearside Biomedical (NASDAQ:CLSD) announced that its licensing partner, REGENXBIO (NASDAQ:RGNX) has dosed the first patient in its Phase 2 clinical trial to evaluate the suprachoroidal delivery of RGX-314, using Clearside’s SCS Microinjector for the treatment of wet age-related macular degeneration.

Clearside Bio nabs new patents in U.S. and Europe (NASDAQ:CLSD)

From Seeking Alpha Aug 26, 2020

Clearside Biomedical (NASDAQ:CLSD) perks 7% premarket after securing three additional patents in the U.S. and Europe.

The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September

From Benzinga Aug 11, 2020

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Allovir Inc (NASDAQ: ALVR) BioLife Solutions Inc (NASDAQ: BLFS) BioSpecifics Technologies Corp. (NASDAQ: BSTC) (...

Navellier Ratings

Powered by Portfolio Grader

Total Grade

A

Strong Buy